Bharat Parenterals Ltd

Bharat Parenter. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Bharat Parenterals Ltd

₹ 1,326 0.22%
18 Apr 2:53 p.m.
bplindia.in BSE: 541096
About

Bharat Parenterals Ltd. is a Gujarat based pharmaceutical company producing general and B-lactum group of drugs as well as antiretroviral drugs. [1]

Key Points

Product Portfolio
The Co has a portfolio of over 500 formulations. It produces pharmaceuticals across categories such as B-LACTAM Antibiotics, Anti Retroviral, Cephalosporins Antibiotics, Antiprotozoal / Anthelmintic Respiratory, Antiallergic, Cleansing Agents /Skin Infections, Cardiovascular System, Anti Diabitic, Anti Fungal etc. [1]

Website BSE
  • Market Cap ₹ 766 Cr.
  • Current Price ₹ 1,326
  • High / Low ₹ 1,465 / 321
  • Stock P/E 49.9
  • Book Value ₹ 337
  • Dividend Yield 0.06 %
  • ROCE 11.3 %
  • ROE 9.01 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is expected to give good quarter

Cons

  • The company has delivered a poor sales growth of 9.80% over past five years.
  • Company has a low return on equity of 12.4% over last 3 years.
  • Company might be capitalizing the interest cost
  • Dividend payout has been low at 0.88% of profits over last 3 years
  • Company has high debtors of 188 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
49.55 40.62 60.84 60.40 38.46 52.31 26.09 81.90 59.02 50.97 69.91 59.81 59.82
43.89 38.04 50.20 50.40 35.78 47.92 24.28 72.71 56.38 44.75 59.46 55.49 53.21
Operating Profit 5.66 2.58 10.64 10.00 2.68 4.39 1.81 9.19 2.64 6.22 10.45 4.32 6.61
OPM % 11.42% 6.35% 17.49% 16.56% 6.97% 8.39% 6.94% 11.22% 4.47% 12.20% 14.95% 7.22% 11.05%
2.59 1.53 1.76 2.52 1.31 2.19 1.54 6.41 3.48 0.31 2.10 2.60 1.26
Interest 0.17 0.02 0.29 0.16 0.21 0.31 0.25 0.34 0.79 0.80 0.89 0.63 0.58
Depreciation 1.64 1.69 1.74 1.72 1.64 1.56 1.54 1.46 1.44 1.44 1.58 1.75 1.82
Profit before tax 6.44 2.40 10.37 10.64 2.14 4.71 1.56 13.80 3.89 4.29 10.08 4.54 5.47
Tax % 15.99% 24.58% 25.75% 25.85% 41.59% 15.71% 28.21% 28.62% 36.50% 47.09% 30.46% 46.48% 33.46%
5.41 1.81 7.70 7.89 1.25 3.97 1.12 9.85 2.47 2.27 7.01 2.43 3.64
EPS in Rs 9.44 3.30 13.49 13.88 2.34 7.00 2.03 17.18 4.94 4.31 13.02 6.10 6.55
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
124 111 137 220 228 205 212 218 241
114 105 124 191 200 179 183 198 213
Operating Profit 10 7 12 29 28 25 29 20 28
OPM % 8% 6% 9% 13% 12% 12% 14% 9% 11%
5 8 7 13 11 9 7 12 6
Interest 1 1 1 1 1 1 1 2 3
Depreciation 4 6 6 6 6 6 7 6 7
Profit before tax 9 7 13 35 33 27 28 24 24
Tax % 31% 8% 29% 39% 26% 25% 25% 33%
6 7 9 21 24 20 21 16 15
EPS in Rs 11.26 12.03 15.92 37.09 42.13 35.59 36.45 28.47 29.98
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 3%
Compounded Sales Growth
10 Years: %
5 Years: 10%
3 Years: -2%
TTM: 10%
Compounded Profit Growth
10 Years: %
5 Years: 11%
3 Years: -14%
TTM: -12%
Stock Price CAGR
10 Years: %
5 Years: 44%
3 Years: 55%
1 Year: 294%
Return on Equity
10 Years: %
5 Years: 16%
3 Years: 12%
Last Year: 9%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 6 6 6 6 6 6 6 6 6
Reserves 51 58 67 88 112 138 160 177 189
19 6 9 5 1 12 18 50 100
44 40 50 60 68 43 42 118 134
Total Liabilities 120 110 132 159 188 199 226 350 429
35 31 34 35 33 45 41 42 51
CWIP 0 0 0 1 12 0 26 99 141
Investments 0 1 1 1 0 43 11 0 0
85 79 98 121 142 111 148 209 236
Total Assets 120 110 132 159 188 199 226 350 429

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
0 -2 6 20 14 24 -1 22
0 -2 -8 -9 -13 -43 -7 -78
0 -8 4 -4 -3 10 9 61
Net Cash Flow 0 -11 2 7 -1 -8 2 4

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 130 143 157 106 127 121 126 188
Inventory Days 62 70 60 59 71 61 56 100
Days Payable 171 168 110 83 104 71 64 155
Cash Conversion Cycle 21 45 107 82 93 111 118 134
Working Capital Days 45 64 92 76 89 112 157 156
ROCE % 11% 18% 39% 31% 20% 17%

Shareholding Pattern

Numbers in percentages

Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
74.42% 74.42% 74.42% 74.42% 73.84% 73.84% 73.84% 73.84% 73.84% 73.84% 73.84% 73.84%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
25.57% 25.57% 25.57% 25.57% 26.15% 26.15% 26.16% 26.16% 26.15% 26.16% 26.15% 26.15%
No. of Shareholders 2,5723,1222,9122,8052,7962,7652,7002,6082,5152,4852,4812,397

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls

  • Feb 2024
    Transcript
    Notes
    PPT